Allist(SH:688578)2022-04-26 16:00Financial Performance - The company's revenue for Q1 2022 was ¥111,157,103.86, representing a year-over-year increase of 202.32%[3] - The net profit attributable to shareholders was -¥22,673,403.02, with a net profit excluding non-recurring items of -¥37,258,658.95[3] - Total operating revenue for Q1 2022 was CNY 111,157,103.86, a significant increase from CNY 36,767,738.1 in Q1 2021, representing a growth of approximately 202.5%[19] - Net profit for Q1 2022 was a loss of CNY 22,673,403.02, an improvement from a loss of CNY 44,298,866.33 in Q1 2021, reflecting a reduction in losses by approximately 48.8%[20] Research and Development - Research and development expenses totaled ¥49,596,570.97, accounting for 44.62% of revenue, a decrease of 56.48 percentage points compared to the previous year[3] - Research and development expenses for Q1 2022 were CNY 49,596,570.97, up from CNY 37,172,562.43 in Q1 2021, marking an increase of about 33.4%[19] - The company is advancing the Phase Ib clinical trial for Fumetinib targeting EGFR 20 exon insertion mutations, which currently has no effective drugs approved in China[13] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,071,165,464.19, a decrease of 1.89% from the end of the previous year[3] - The total current assets as of March 31, 2022, were RMB 2.29 billion, a decrease from RMB 2.37 billion at the end of 2021[15] - Total liabilities for Q1 2022 were CNY 102,839,222.84, down from CNY 156,994,583.02 in the previous period, indicating a reduction of approximately 34.4%[17] Cash Flow - The company's cash flow from operating activities was -¥51,249,765.31, indicating increased operational expenditures[3] - Cash inflow from operating activities for Q1 2022 was 96,614,850.97 CNY, a significant increase from 25,709,567.52 CNY in Q1 2021, representing a growth of approximately 275%[22] - The net cash flow from operating activities for Q1 2022 was -51,249,765.31 CNY, an improvement from -86,708,716.89 CNY in Q1 2021[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,366[8] - The largest shareholder, Shanghai Qiaoke Enterprise Development Co., Ltd., held 32.17% of the shares, totaling 144,776,786 shares[8] Sales and Marketing - The company's sales expenses rose by 94.22%, primarily due to increased marketing activities and related costs[6] - Fumetinib was included in the national medical insurance directory in December 2021, which positively impacted its sales in Q1 2022 despite some negative effects from COVID-19[12] - The exclusive promotion agreement with Jiangsu Fosun is expected to enhance market coverage and commercial potential for Fumetinib, benefiting more patients in China[12] Clinical Trials - The Phase III clinical trial results for Fumetinib showed a median progression-free survival (PFS) of 20.8 months compared to 11.1 months for the control group, representing an increase of 9.7 months and a 56% reduction in the risk of disease progression or death[13] Government Grants - The company received government grants amounting to ¥1,233,524.25 during the reporting period[4]